Management of Bipolar I Depression: Clinical Utility of Lurasidone by Findlay, Lillian Jan et al.
University of Kentucky
UKnowledge
Nursing Faculty Publications College of Nursing
1-8-2015
Management of Bipolar I Depression: Clinical
Utility of Lurasidone
Lillian Jan Findlay
University of Kentucky, jan.findlay@uky.edu
Peggy El-Mallakh
University of Kentucky, peggy.el-mallakh@uky.edu
Rif S. El-Mallakh
University of Louisville
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/nursing_facpub
Part of the Nursing Commons
This Article is brought to you for free and open access by the College of Nursing at UKnowledge. It has been accepted for inclusion in Nursing Faculty
Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
Repository Citation
Findlay, Lillian Jan; El-Mallakh, Peggy; and El-Mallakh, Rif S., "Management of Bipolar I Depression: Clinical Utility of Lurasidone"
(2015). Nursing Faculty Publications. 18.
https://uknowledge.uky.edu/nursing_facpub/18
Management of Bipolar I Depression: Clinical Utility of Lurasidone
Notes/Citation Information
Published in Therapeutics and Clinical Risk Management, v. 11, p. 75-81.
© 2015 Findlay et al.
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution –
Non Commercial (unported, v3.0) License. The full terms of the License are available at
http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without
any further permission from Dove Medical Press Limited, provided the work is properly attributed.
Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information
on how to request permission may be found at: http://www.dovepress.com/permissions.php
Digital Object Identifier (DOI)
http://dx.doi.org/10.2147/TCRM.S57695
This article is available at UKnowledge: https://uknowledge.uky.edu/nursing_facpub/18
© 2015 Findlay et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
Therapeutics and Clinical Risk Management 2015:11 75–81
Therapeutics and Clinical Risk Management Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
75
R e v i e w
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/TCRM.S57695
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Abstract: Lurasidone is a benzisothiazol derivative second-generation antipsychotic. It has 
been approved in the United States and Europe for treatment of acute schizophrenia and bipolar 
depression. In type I bipolar subjects, treatment with lurasidone monotherapy of adjunctive 
therapy to lithium or valproic acid with doses of 20 to 120 mg once daily with food, results in 
statistically and clinically significant reduction of depressive symptoms. Patients experience 
relatively few side effects, which include somnolence, akathisia, nausea, and other gastrointes-
tinal upset. Dopamine related side effects, such as Parkinsonism and elevated prolactin, are rare 
and mild. Longer term safety data obtained in 6 months long, open continuation observation 
periods, suggest that metabolic related elevations in weight, glucose, and lipids are absent or 
minimal. The mechanism of action of lurasidone is not known, but the data are compatible with 
antagonism of the serotonin 7 receptor. Lurasidone is a new option for the treatment of bipolar 
depression with relatively few side effects.
Keywords: lurasidone, bipolar disorder, bipolar depression, adjunctive therapy
Introduction
The treatment of depression in patients diagnosed with bipolar disorder presents con-
siderable challenges to the clinician. Depression is a key feature of bipolar disorder, 
and the total number of depressive episodes may be present in up to a third or half of 
a patient’s life.1–4 These depressive episodes have a variety of clinical presentations; 
for example, the symptoms may meet full diagnostic criteria for a major depressive 
episode, or may be subsyndromal. Alternatively, the symptoms may be a manifestation 
of the commonly comorbid dysthymic disorder.2,3,5,6 Additionally, depressive symptoms 
frequently occur due to comorbid medical conditions that are common in patients with 
bipolar illness. These include sleep apnea, thyroid disease, diabetes, cardiac disease, 
and other chronic medical conditions.7–12
Pharmacologic treatment of depression in bipolar illness is complicated by 
a dearth of efficacy and safety data. While the current use of antidepressants in 
bipolar disorder has declined to as low as 34% of patients,13 their use in this popu-
lation remains controversial.14 Some reviews report that antidepressants are safe 
and effective;15 however, others report that antidepressants are ineffective and 
potentially harmful.16 Current reports on efficacy suggest that antidepressants 
appear to be effective in bipolar depression when used alone17,18 or when added to 
an antipsychotic,19 but are ineffective in placebo-controlled trials in which they are 
added to a mood stabilizer.20–22 Furthermore, while much research has focused on 
the problem of induction of a manic state due to the use of antidepressants, research 
suggests that antidepressants can induce at least three distinct problems in bipolar 
patients. Antidepressants can indeed increase the likelihood of a manic switch,21 
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or any switch by accelerating cycling,4,23 and increase the 
likelihood of both acute and chronic depression in rapid 
cycling patients.24,25 
Thus, clinicians are often presented with a quandary in 
clinical practice when their patients with bipolar disorder 
present with depression since the evidence-based options 
available for treating such a patient are limited.26 However, 
clinical research increasingly supports the use of anti-
psychotic medications as an effective treatment option for 
depression in bipolar disorder.27,28 For example, lurasidone, 
a second-generation antipsychotic that is already approved 
for the treatment of schizophrenia,29,30 has been approved by 
the United States Food and Drug Administration (FDA) for 
the treatment of bipolar depression.31,32 The agent has dem-
onstrated efficacy and safety in this population. Its presumed 
mechanism of action appears to be unique. This paper will 
review the available information about lurasidone for the 
management of bipolar depression.
Pharmacokinetics, 
pharmacodynamics, and 
pharmacology
Lurasidone is a benzisothiazol derivative second-generation 
antipsychotic. It has a complex multi-ring structure that is 
minimally soluble in water. It is supplied as lurasidone hydro-
chloride in unscored 20, 40, 60, 80, and 120 mg tablets. 
It is likely that lurasidone is absorbed in the stomach. 
For this reason, it is more effectively absorbed when taken 
with food.33 This effect is similar to that observed with 
ziprasidone.34,35 In both cases a meal of approximately 
350 calories for lurasidone and 500 calories for ziprasidone, 
maximizes and stabilizes absorption of the drug.34,35 Fat 
content of the meal does not alter the absorption. Absorption 
is increased approximately two to three times, and maximal 
serum concentration is increased about three fold.33 Once 
absorbed, lurasidone is highly plasma protein bound (99.8% 
is bound to albumin and α-1-glycoprotein).36
It is metabolized predominantly by the cytochrome P450 
isozyme 3A4. It is broken down by oxidative N-dealkylation, 
hydroxylation of norbornane ring, and S-oxidation. There 
are two active metabolites (ID-14283 and ID-14326) 
and three inactive metabolites (ID-20219, ID-20220, and 
ID-11614).33 The active metabolites comprise only about 
28% of the breakdown products of lurasidone, and have a 
shorter half-life, thus most of the action is believed to be due 
to the parent drug.36 The half-life of lurasidone is 18 hours 
for a 40 mg oral dose, so it can be taken once daily. Steady 
state is achieved within 5 to 7 days.33,36 Because lurasidone 
is not a substrate for CYP1A2, smoking does not alter 
metabolism. The majority of the metabolic remnants of 
lurasidone end up in the feces (80%), with a small fraction 
in the urine (9%).
Lurasidone interacts with many receptors, and is antago-
nistic at most of them. The principal ones are dopamine 
D
2
 (K
i
 =1.68 nM), serotonin 5HT
7
 (K
i
 =0.5 nM), 5HT
2A
 
(K
i
 =0.5 nM in human and 2.0 nM in rat), and 5HT
1A
 (K
i
 =6.4 
nM in human and 6.8 nM in rat).36 For the 5HT
1A
 receptor, 
lurasidone is classified as a partial agonist; but the partial 
agonist effect is only 33% that of serotonin.37 At higher doses 
it may interact with the adrenergic α
2A
 (K
i
 =40.7 nM), and α
2C
 
(K
i
 =10.8 nM). It does not interact with the histamine H
1 
or 
muscarinic M
1
 (K
i
 >1,000 nM for both).36 Receptor binding in 
humans as measured by positron emission  tomography  (PET) 
reveals that doses below 40 mg do not achieve adequate D
2
 
binding for an antipsychotic effect (41%–43% for 10 mg, 
and 51%–55% for 20 mg).38,39 With a 40 mg dose the D
2
 
binding is 63%–67%, and increases to 77%–79% with 60 
mg. Interestingly, higher doses do not increase receptor 
occupancy (73%–79% with 80 mg dose).39 This observa-
tion may explain why Parkinsonism and elevated prolactin 
are uncommon with lurasidone in these studies, particularly 
with lower doses.31 However, D
2
 receptor occupancy is more 
closely related to blood levels than to dosage of lurasidone, 
because of the significant variability in drug concentrations 
across individuals.40
The interaction with 5HT
7 
is believed to be particularly 
important for the antidepressant effect in bipolar illness. 
Blockade of this receptor with selective 5HT
7
 antagonists 
or knocking out the 5HT
7
 gene, improve symptoms of 
“depression” in animal models of depression.41–43 A pure 
5HT
7 
antagonist reduced depressive symptoms in a preclini-
cal rodent study, but did not separate from placebo due to 
a high placebo response rate.44 Testing in animal models of 
depression and anxiety with lurasidone demonstrates that it 
is effective in reducing depressive symptoms in animals.45 
Part of this effect may be due to an increase in dopamine 
efflux in the frontal cortex that is induced by lurasidone 
blockade of 5HT
7
.46,47 This effect is also believed to medi-
ate the pro-cognition effect of lurasidone.48–51 Additionally, 
lurasidone appears to modulate the reductions in brain-
derived neurotrophic factor and promote neuroplasticity 
in animal models of stress and depression.52,53 A positive 
effect on brain-derived neurotrophic factor appears to be a 
marker for effective antidepressant agents.54 None of these 
potential mechanisms of action have been demonstrated as 
being central in human studies.
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Efficacy of lurasidone in bipolar 
depression
Two randomized, double-blinded controlled clinical trials 
have examined the efficacy of lurasidone in the treatment 
of bipolar I depression (Figures 1 and 2).31,32 Lurasidone 
was tested as monotherapy at 20–60 mg/day (N=166) and 
80–120 mg/day (N=169), with a placebo comparison (N=170) 
(Figure 1). Findings indicated that after 6 weeks, scores on 
the Montgomery–Ȧsberg Depression Scale (MADRS) were 
equally and significantly decreased in both the 20–60 mg/day 
group (-15.4) and in the 80–120 mg/day group (-15.4), 
compared to placebo (-10.7) (Figure 1). Response, defined 
as 50% improvement on the MADRS, was achieved by 
53% of those receiving the low dose, and 51% of those 
receiving the high dose, compared to 30% of those receiving 
placebo. The number needed to treat (NNT) was 5 for both 
groups. Similarly, remission, defined as a MADRS score 
of 12, was achieved by 42% in the low dose group and 
40% in the high dose group, compared to 25% on placebo. 
The NNT for remission was 6 in the low dose group and 7 
in the high dose group. In addition, both treatment groups 
showed significantly greater endpoint decreases in depression 
severity scores on the Clinical Global Impressions Scale for 
Bipolar Illness compared to placebo. Endpoint decreases 
were -1.8 for the 20–60 mg/day group, -1.7 for the 80–120 
mg/day group, and -1.1 for the placebo group. 
For both treatment groups, significant improvements 
were seen on several domains of the MADRS, including in 
reported and apparent sadness, inner tension, “inability to 
feel”, lassitude, and pessimistic thoughts. The lurasidone 
20–60 mg/day group showed significant improvements in 
sleep, and the 80–120 mg/day group showed significant 
improvements in concentration. No significant changes 
were seen in appetite or suicidal ideation in either treat-
ment group compared to placebo. Both treatment groups 
also reported significant reductions in anxiety compared to 
placebo, as measured by the Hamilton Anxiety Rating Scale. 
Findings from this study further indicate that participants 
in both treatment groups reported significantly improved 
quality of life and life satisfaction, along with significantly 
reduced disability.32
A second randomized, controlled trial examined the 
effectiveness of lurasidone as an adjunct to lithium or 
valproate in the treatment of bipolar I depression.32 All 
patients met criteria for a moderate major depression despite 
documented therapeutic levels of lithium or valproate. The 
treatment group (N=183) was started on lurasidone at 20 mg, 
which was increased to 60 mg by the end of the first week 
of the study. After the first week, dosages could be adjusted 
within a range of 20–120 mg/day at weekly intervals, with 
increases or decreases of 20 mg, based on clinical judgment.32 
Figure 1 The efficacy outcome at the end of 6 weeks of treatment of acutely 
depressed type i bipolar patients treated with placebo, or monotherapy with 
lurasidone 20–60 mg/day, or lurasidone 80–120 mg/day. 
Notes: The effect size for the low dose arm is 0.61, and for the high dose arm 0.50; 
these are considered medium in size. P-values are versus placebo arm.
Abbreviation: MADRS, Montgomery–A˙sberg Depression Rating Scale.
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Figure 2 The efficacy outcome at the end of 6 weeks of treatment of acutely 
depressed type i bipolar patients treated with lithium or valproate to which either 
placebo was added or lurasidone 20–80 mg/day. 
Notes: The effect size is 0.34. P-values are versus placebo arm.
Abbreviations: Li, lithium; vPA, valproate; MADRS, Montgomery–A˙sberg Depression 
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The control group (N=165) received placebo added to the 
lithium or valproate. 
Depression, anxiety, quality of life, life satisfaction, and 
disability were measured at baseline and at 6 weeks. Findings 
indicate that the group treated with lurasidone + lithium/val-
proate had significantly improved depression, as measured by 
the MADRS (Figure 2). The least squares mean change of the 
MADRS score for the lurasidone + lithium/valproate group 
was -17.1, compared to -13.5 for the placebo group. In addi-
tion, significantly shorter time to remission was seen in the 
lurasidone + lithium/valproate group (35 days) compared to 
the placebo group (43 days). Response was achieved by 57% 
of patients receiving lurasidone + lithium/valproate com-
pared to 42% of those on placebo + lithium/valproate. The 
NNT was 7. Remission rates were 50% in the lurasidone + 
mood stabilizer group, versus 35% in the placebo + mood 
stabilizer group; with an NNT of 7.
Several domains of the MADRS showed significant 
improvement in the lurasidone + lithium/valproate group 
compared to placebo, including reported and apparent 
sadness, sleep, lassitude, inability to feel, and pessimistic 
thoughts. However, no significant differences were seen in 
inner tension, appetite, concentration difficulties, and suicidal 
ideation. In addition, the lurasidone + lithium/valproate group 
reported significant reductions in anxiety and disability, along 
with significant improvements in quality of life, enjoyment, 
and life satisfaction, compared to the placebo group. 
A separate adjunctive, placebo-controlled study failed 
to separate from placebo. This study had a design similar 
to the previous study, while improvement was noted in the 
lurasidone arm, it did not separate from placebo. The safety 
data (see the “Lurasidone Safety and tolerability” section) 
includes patients from this unpublished failed study.
A 6 months open observation period was performed for 
patients in both of these studies who wished to remain in the 
study. Patients on placebo were switched to active medica-
tion. The study has not yet been published and symptom data 
are not available for this review.
Lurasidone safety and tolerability  
in bipolar depression
The FDA approved lurasidone for schizophrenia in 2010 
and subsequently in 2013 for bipolar depression.55 It is 
considered as safe, well-tolerated, and efficacious in these 
conditions.31,32,56,57 In a systematic review of the literature 
from June 2009 to February 2014, lurasidone, compared 
to other recently approved second-generation atypical anti-
psychotics such as paliperidone, iloperidone, and asenapine, 
was considered by researchers to be less likely to produce 
the metabolic side effects of weight gain, hyperlipidemia, 
hypercholesterolemia, and hyperglycemia, and was not linked 
to significant electrocardiogram (ECG) abnormalities.58–61
Among a total of eleven articles found that described 
the safety and tolerability of lurasidone in the treatment of 
schizophrenia or major depressive episodes associated with 
bipolar I disorder, four were peer-reviewed, double-blind, 
placebo-controlled studies,31,32,56,57 and another was a meta-
analysis.62 Two of the peer-reviewed studies examined the 
use of lurasidone in the treatment of bipolar I disorder.31,32 
In the monotherapy study, 505 adults 18–75 years of 
age were recruited.31 The three study groups comprised 
of patients receiving 6 weeks of lurasidone flexible daily 
oral doses in the ranges of either 20–60 mg or 80–120 mg, 
or placebo.31 The majority of adverse events were rated 
as mild to moderate and 10% ranked as severe across 
groups.31 Dropout rates due to adverse events were similar 
across groups (5.9%–6.6%). There was no statistically or 
clinically-significant change in weight, lipid, cholesterol, 
or prolactin levels, glycemic control, waist circumference, 
or ECG readings.31 The proportion of patients with 7% 
increase in weight from baseline was 4.2% in the 20–60 mg 
group, 0.7% in both the 80–120 mg and placebo groups.31 
The high dose group experienced more adverse effects with a 
modest occurrence of the incidence of nausea (N=29, 17.4%), 
akathisia (N=18, 10.8%), somnolence (N=11, 13.8%), seda-
tion (N=12, 7.2%), vomiting (N=10, 6.0%) and extrapyrami-
dal side effects (N=15, 9.0%) (Table 1). Females experienced 
a higher mean increase in prolactin (7.5 ng/mL) compared to 
males (2.6 ng/mL).31 Treatment-emergent mania did not dif-
fer across the groups. There were low rates of serious adverse 
events across groups with no deaths, suicidal behaviors or 
suicides during the study.31 
In the trial comparing the safety and efficacy of lurasidone 
added to stable doses of lithium or valproate versus placebo 
added to lithium or valproate in depressed bipolar I patients, 
348 adults 18–65 years of age were studied.32 The lurasidone 
+ lithium/valproate group most commonly experienced the 
adverse events of nausea (17.5%), somnolence (8.7%), tremor 
(8.2%), akathisia (7.7%), insomnia (7.1%), and Parkinsonism 
(15.3%). Discontinuation rates due to adverse events were 6% 
in this group versus 7.9% in the placebo + lithium/valproate 
group. Additionally, lurasidone did not significantly increase 
body weight, lipids, glucose, or prolactin levels.32 
In both bipolar I studies, overall adverse events with 
lurasidone versus placebo included extrapyramidal events 
24% versus 13%, akathisia 11% versus 5%, and Parkinsonism 
Therapeutics and Clinical Risk Management 2015:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
79
Management of bipolar i depression
13% versus 8%.56 Similarly, in the two studies examining the 
safety, tolerability, and efficacy of lurasidone in the treatment 
of acute schizophrenia, researchers generally found that the 
most commonly experienced side effects were akathisia, 
headache, gastrointestinal upset (nausea, vomiting, and dys-
pepsia), insomnia, somnolence, and sedation (Table 1).56,57 
In the 6 months open observation study of patients receiv-
ing lurasidone monotherapy (N=130), there was no additional 
weight gain (0.0 kg).56 Similarly fasting glucose increased 
by 1.2 mg/dL, total cholesterol dropped by 0.5 mg/dL, tri-
glycerides dropped by 1.0 mg/dL, and prolactin dropped by 
1.2 ng/dL.56 Patients receiving lurasidone as adjunct (N=88) 
had more changes, but still quite modest. Over the 6 months 
period, weight increased by 1.3 kg, fasting glucose increased 
by 1.7 mg/dL, total cholesterol dropped by 0.9 mg/dL, tri-
glycerides increased by 5.3 mg/dL, and prolactin dropped 
by 2.9 ng/dL.56 
Lurasidone is metabolized primarily through the cyto-
chrome P450 3A4, and it should be used with caution 
in combination with strong CYP3A4 inhibitors such as 
ketoconazole, clarithromycin, and voriconazole (the latter 
two no longer in the American market), or inducers such as 
rifampin, St John’s Wort, phenytoin, and carbamazepine.56 
Dose adjustments are generally recommended in patients 
with renal and hepatic impairment.56 Renal impairment may 
require initial dosing at 20 mg/day with a maximum dose of 
80 mg/day for creatinine clearance 50 mg/min. However, 
since most of the deactivation of the drug is hepatic, these 
recommendations are precautionary. For hepatic impair-
ment patients with a Child–Pugh Class B, starting dose is 
20 mg/day with a maximum dose of 80 mg/day; Child–Pugh 
Class C patients should start at 20 mg/day with a maximum 
dose of 40 mg/day.56 
Last, safety and tolerability in pediatric and geriatric 
populations diagnosed with either bipolar I disorder or 
schizophrenia has not been established.56 However, in a 
review of the pharmacologic and clinical profile of lurasi-
done, according to industry data, no dose adjustment was 
needed in patients 65–85 years of age since no significant 
differences were found in concentrations of lurasidone among 
adult and geriatric patients diagnosed with schizophrenia.62 
Furthermore, because of improved cognition experienced in 
geriatric patients taking lurasidone and its lower potential 
for anticholinergic and hypotensive effects, further study is 
warranted in this age group.62 It should be remembered that 
all antipsychotics carry an FDA class warning that death 
in severely demented, agitated patients with psychosis is 
nearly twice as common as in patients not receiving such 
medications.
Conclusion
Lurasidone is a new second-generation antipsychotic that 
appears to have the desired property of antagonizing 5HT
7
 
receptors at relatively low doses. It is believed that this 5HT
7
 
blockade mediates the clinical improvement in depression. 
This effect occurs when lurasidone is administered alone 
or in combination with a mood stabilizer. The adverse 
effects seen in patients with bipolar illness receiving lur-
asidone are uncommon and generally mild. The effect on 
metabolic parameters is very favorable. Lurasidone is a new 
safe and effective option for the management of bipolar 
depression.
Disclosure
RSE has research funding from Merck and AssureRx. He is 
also a speaker for AstraZeneca, Lundbeck, Otsuka, Takeda, 
Table 1 Spontaneously reported adverse events (Aes) in the three registrational trials for lurasidone 
Event Low dose  
(n=164)
High dose  
(n=167)
Placebo  
(n=168)
Li/VPA + lurasidone  
(n=360)
Li/VPA + placebo 
(n=334)
Tremor 18.2%  4.3%
Nausea 10.4% 17.4% 7.7% 17.5% 11.0%
Somnolence  7.3% 13.8% 6.5%  8.7%  4.3%
Headache 10.4% 12.3%
Akathisia  7.9% 10.8%  2.4%
insomnia  7.1%  5.5%
Dry mouth  6.1%  3.6%  4.2%
Diarrhea  4.9%  3.0%  1.8%  4.4%  6.7%
Discontinuation due to Ae  7.0%  6.0%  6.0%  7.9%  6.0%
Notes: Only Aes occurring at 5% are reported. The United States Food and Drug Administration does not perform statistical analysis on Aes. Low dose = lurasidone 
20–60 mg/day; High dose = lurasidone 80–120 mg/day; Li/vPA + lurasidone = lurasidone 20–80 mg added to lithium or valproate; Li/vPA + placebo = placebo added to 
lithium or valproate.
Abbreviations: Li, lithium; vPA, valproate.
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